Analysts at GlobalData have previously forecast that Spravato will generate global sales of approximately $383 million by 2029, with its potential pegged back by its cost and a requirement for two ...

Mental health is a vital aspect of overall well-being, especially for students who face unique pressures and challenges. From ...

When Dr. Husseini Manji was developing the first-in-class depression medication Spravato at Johnson & Johnson he encountered plenty of naysayers. “A lot of people didn’t think it would work ...

The FDA has required Spravato be administered under a strict risk evaluation system to track this ... These companies have ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Two accounting terms this article will look at are transfer price and standard cost. While an item's standard cost can be used to determine its transfer price, the two values are inherently different.

U.S. NeuroStar Advanced Therapy System revenue for the three months ended September 30, 2024 was $4.1 million, an increase of 14% compared to $3.6 million in the third quarter of 2023. For the three ...

U.S. NeuroStar Advanced Therapy System revenue for the three months ended September 30, 2024 was $4.1 million, an increase of 14% compared to $3.6 million in the third quarter of 2023. For the three ...

In this article, we are going to take a look at where Costco Wholesale Corporation (NASDAQ:COST) stands against the other grocery stocks. Food prices, along with energy prices, tend to be ...

Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Car ownership costs go far beyond what you pay for a car. A key question is whether you can afford the drip, drip of maintenance and repairs for as long as you own it. We found that there are ...

Spravato was launched with an annual price tag of around $32,400, which the Institute for Clinical and Economic Review (ICER) concluded was around 25% to 52% too high to be cost effective.